PBT 2

Drug Profile

PBT 2

Alternative Names: PBT-2

Latest Information Update: 20 Oct 2016

Price : $50

At a glance

  • Originator Prana Biotechnology
  • Class Antidementias; Dimethylamines; Hydroxyquinolines; Ionophores; Small molecules
  • Mechanism of Action Chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Alzheimer's disease

Highest Development Phases

  • Phase II Alzheimer's disease; Huntington's disease

Most Recent Events

  • 18 Oct 2016 Efficacy data from the phase IIa Reach2HD trial in Huntington's disease released by Prana Biotechnology
  • 27 Jul 2016 Pharmacodynamics data from a preclinical study in Alzheimer's disease released by Prana Biotechnology
  • 30 Jun 2015 Adverse events data from the IMAGINE Extension trial in Alzheimer's disease released by Prana Biotechnology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top